Clinical review report Telotristat (Xermelo) (Ipsen Biopharmaceuticals Canada Inc.)
The objective of this report is to perform a systematic review of the beneficial and harmful effects of telotristat ethyl for the treatment of refractory carcinoid syndrome diarrhea, in combination with somatostatin analogue (SSA) therapy, in patients whose disease inadequately controlled by SSA the...
| Main Author: | |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | Inglés |
| Published: |
Ottawa, Ontario :
Canadian Agency for Drugs and Technologies in Health
2019.
|
| Subjects: | |
| See on Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820281706719 |
| Summary: | The objective of this report is to perform a systematic review of the beneficial and harmful effects of telotristat ethyl for the treatment of refractory carcinoid syndrome diarrhea, in combination with somatostatin analogue (SSA) therapy, in patients whose disease inadequately controlled by SSA therapy alone. |
|---|---|
| Physical Description: | 1 online resource (1 PDF file (86 pages)) : illustrations |
